Key takeaways
- BPC-157 is a synthetic 15-amino-acid peptide, reported to be a fragment of a protein found in human gastric juice.
- Most published research is in cells and animals: 35 of the 36 studies in a 2025 systematic review were preclinical.
- Human evidence is limited to a few small studies, most without a control group. The only randomised, placebo-controlled data are in conference abstracts; no peer-reviewed randomised trial has been published.
- In its 2026 review, FDA found no approved product containing it in any country, and WADA prohibits it in sport at all times.
01What is BPC-157?

BPC-157 is a pentadecapeptide, a chain of 15 amino acids. It was first described in the early 1990s as a fragment of a protein, called BPC, reported to be found in human gastric juice. What researchers use is made synthetically; FDA’s 2026 review covered the free base and the acetate salt, and noted that most studies do not say which form they used.
02Has BPC-157 been studied in humans?
A 2025 systematic review of musculoskeletal studies found 35 of its 36 included studies were preclinical; the one human study had no control group.
Source: Vasireddi et al., HSS J, 2025
03What mechanisms have cell and rodent studies proposed for BPC-157?
In 2026, FDA staff wrote that BPC-157’s molecular targets “have not been identified” and its mechanisms of action “remain poorly understood”. The mechanisms below are hypotheses from cell and rodent studies, not findings in people.

Higher expression reported in cell and rodent studies, including the growth-hormone receptor in cultured tendon cells.
Signs of new blood-vessel growth (angiogenesis) reported in cell and rodent studies.
Effects on nitric-oxide production reported in rodent studies.
Lower release or expression of inflammatory factors reported in cell and rodent studies.
In rat tendon cells and tissue pieces in the lab, more cell outgrowth and migration, with activation of the FAK–paxillin pathway (Chang 2011). That is not evidence of an effect in animals or people.
04How strong is the evidence on BPC-157?
| Area studied | Main evidence | Human data | Grade |
|---|---|---|---|
| Gut lining and ulcers | Rodent ulcer, colitis and fistula models | Randomised data only in conference abstracts: a tolerability study and a colitis trial that FDA staff found inadequate to support efficacy or safety | Preclinical |
| Tendon and ligament | Rodent transection and detachment models | None controlled | Preclinical |
| Muscle injury | Rodent muscle-injury models | None controlled | Preclinical |
| Joint pain | — | One retrospective case series in knee pain, no control group | Very limited |
| Bone | Animal bone-injury models | None | Preclinical |
05What hasn't BPC-157 research shown?

That effects in rodents translate to people.
No randomised, controlled human efficacy trial has been published as a full peer-reviewed paper; the only one is known from a 2005 conference abstract.
A characterised human safety profile.
FDA staff concluded that “there is insufficient clinical safety information to characterize the safety profile” of BPC-157.
Dose–response in animals.
FDA staff noted that dose–response relationships in the rodent gut and liver models “have not been established”.
How BPC-157 behaves in the human body.
FDA staff found no human pharmacokinetic data for most routes, and in the two studies that measured blood levels BPC-157 was not detected or mostly below the assay’s limit.
06Is BPC-157 an approved medicine? Status, Nov 2026
No. BPC-157 is not an approved medicine in the US, and in its 2026 review FDA found no approved product containing it in any country.
- Sep 2023FDA places BPC-157 in Category 2
Listed in Category 2 of FDA’s interim compounding policies, the category for bulk substances that may present significant safety risks.
- 22 Apr 2026Out of Category 2
Moved to FDA’s list of substances whose nominations were withdrawn by the nominators. HHS later noted that neither the placement nor the removal changed its status under section 503A.
- 23 Jul 2026Advisory committee votes in favour
FDA’s Pharmacy Compounding Advisory Committee voted in favour of adding BPC-157 to the 503A bulks list. FDA’s drug centre had recommended against. The vote is advice, not a rule.
- 28 Oct 2026HHS enforcement-discretion policy
HHS said it does not intend to act against state-licensed pharmacies, federal facilities and licensed physicians compounding BPC-157 acetate on a patient-specific prescription under ten conditions. The Federal Register notice calls it a draft; it is not binding and not an approval. Products sold as research chemicals are outside it.
- NowStill not an approved medicine
BPC-157 is not an approved medicine in the US, and WADA names it in class S0. Dated record: Is BPC-157 legal?
07What should a BPC-157 COA show?
A certificate of analysis should let you answer these five questions.

A generic or undated COA proves nothing about the vial in front of you.
HPLC measures purity, not identity. Its molecular weight is 1419.5 g/mol (free base).
Look for the chromatogram, not just a percentage.
A named lab can be looked up. If it claims accreditation, check that the test on the report is one the accreditation covers.
Relevant for any material used in cell or animal work.
08Sources
- Vasireddi N, Hahamyan HA, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal, 2025. doi:10.1177/15563316251355551. pubmed.ncbi.nlm.nih.gov/40756949/
- U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193343/download
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol, 2011;110(3):774–780. PMID 21030672. pubmed.ncbi.nlm.nih.gov/21030672/
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 2021;27(4):8–13. pubmed.ncbi.nlm.nih.gov/34324435/
- Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 2026;92(3). PMID 42885452. pubmed.ncbi.nlm.nih.gov/42885452/
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-…
- U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, 2026. hhs.gov returned 403 to our fetch on 18 Nov 2026; read on the Internet Archive capture of 15 Nov 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcemen…
- Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026 (filed 28 Oct 2026); text read on govinfo 18 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.h…
- FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar, content current 6 Aug 2026. www.fda.gov/advisory-committees/advisory-committee-calendar…
- World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027). International Standard; both PDFs read 18 Nov 2026. www.wada-ama.org/en/prohibited-list